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Abstract
Introduction: Cost effectiveness analyses (CEA) can provide useful information on how to invest limited funds, however
they are less useful if different analysis of the same intervention provide unclear or contradictory results. The objective of
our study was to conduct a systematic review of methodologic aspects of CEA that evaluate Interferon Gamma Release
Assays (IGRA) for the detection of Latent Tuberculosis Infection (LTBI), in order to understand how differences affect study
results.
Methods: A systematic review of studies was conducted with particular focus on study quality and the variability in inputs
used in models used to assess cost-effectiveness. A common decision analysis model of the IGRA versus Tuberculin Skin Test
(TST) screening strategy was developed and used to quantify the impact on predicted results of observed differences of
model inputs taken from the studies identified.
Results: Thirteen studies were ultimately included in the review. Several specific methodologic issues were identified across
studies, including how study inputs were selected, inconsistencies in the costing approach, the utility of the QALY (Quality
Adjusted Life Year) as the effectiveness outcome, and how authors choose to present and interpret study results. When the
IGRA versus TST test strategies were compared using our common decision analysis model predicted effectiveness largely
overlapped.
Implications: Many methodologic issues that contribute to inconsistent results and reduced study quality were identified in
studies that assessed the cost-effectiveness of the IGRA test. More specific and relevant guidelines are needed in order to
help authors standardize modelling approaches, inputs, assumptions and how results are presented and interpreted.
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Introduction
Global tuberculosis (TB) control is currently facing great
opportunities, but also great challenges. Opportunities for
improved TB control have increased dramatically over the past
decade as the result of greater funding from governments of low
and middle income countries (LMICs) and from international
donors and funding agencies [1]. At the same time, the number of
new tools, particularly in the area of TB diagnostics, has expanded
rapidly, providing a wide array of potential technologies for
implementation [2]. One of the greatest challenges for govern-
ments and donor agencies is to decide where to invest resources to
achieve the greatest benefit for the most people.
Economic analyses can provide decision makers with more
information on which to base investment decisions, by comparing
costs and resulting health benefits of different approaches. Cost
Effectiveness Analyses (CEA) are one of the most commonly used
economic analyses in published studies [3]. The cost per unit of
outcome or health effect of different interventions can be estimated
and compared [3]. If CEAs are conducted with rigorous,
standardized and transparent methods, results of different analyses
should be comparable and help policy makers reach consensus on
interventions to be implemented in a particular population or
setting [4]. However, if different analyses of the same intervention
produce contradictory results, this may heighten confusion and
even discredit the value of these analyses.
The area of diagnostics for latent TB infection (LTBI) serves as
an excellent example of this phenomenon. Until relatively
recently, a single test – the Tuberculin Skin Test (TST) - was
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A Systematic Review of CEAs of IGRAs
PLOS ONE | www.plosone.org 2 March 2013 | Volume 8 | Issue 3 | e56044the only method to diagnose LTBI. In the past decade, Interferon
Gamma Release Assays (IGRAs) have been approved for use for
this purpose in many countries, leading to a wave of studies of
their accuracy and utility [5,6]. These have included cost-
effectiveness analyses, which have provided seemingly contradic-
tory messages.
In general, systematic reviews are designed to synthesize
evidence after careful assessment of the methodological quality
of all available relevant studies on a particular topic [4]. For
economic analyses in particular, the goal of a systematic review is
not to produce statements about whether a particular intervention
is cost effective, but rather to summarize what is known from
different settings about economic aspects of interventions, as well
as to encourage a more transparent and consistent approach to the
conduct and reporting of economic analyses [4]. The objective of
our study was thus to conduct a systematic review of methodologic
aspects (study quality, inputs and methodologic approach) of CEA
that evaluate IGRA’s for the detection of LTBI, in order to assess
if methodologic differences could account for differences in study
findings and conclusions. A second objective was to develop a
common decision analysis model that could quantify the impact on
predicted costs and effectiveness of the observed differences in
inputs that were used in the studies identified.
Methods
Ethics Statement
An ethics statement was not required for this work.
Systematic Review
Search criteria. We searched for CEA that compared
IGRA’s with at least one other test strategy for diagnosing LTBI.
Included studies used modeling techniques to make predictions
about specific outcomes over time with any analytic horizon. No
limits on year of publication, or language were imposed. Predicted
outcomes of interest included Quality Adjusted Life Years
(QALYs), active TB cases and total costs predicted. Studies were
excluded if they: 1) used animal subjects; 2) assessed detection of
active disease; 3) were conference abstracts or proceedings; 4)
assessed detection of non-tuberculous mycobacterial infection or
disease; and 5) used non-standard tests for LTBI.
Search methods. We searched the following databases from
1947 up to March 15
th 2011: Scopus, Web of Science, Medline,
Embase, Cinhal, Cochrane Library, CRD, Econlit, CEA registry
and Lilacs for relevant studies. An update was performed on
August 31 2011. In addition to these databases, reference lists of
identified publications were also hand searched. A sample search
string used for a Medline database search can be found in Table
S1.
Study selection. Two independent reviewers reviewed all
titles and abstracts in order to select full studies. Full text review to
finalize study selection was done independently by the same two
reviewers and any disagreements were resolved by a third
reviewer.
Data abstraction. A standardized data abstraction form was
developed and piloted on a subset of studies. Once finalized, the
form was used by two reviewers to independently extract data.
Data was extracted on the following topics; 1) General informa-
tion, 2) Model/Economic inputs and assumptions, 3) Study input
data sources, 4) Predicted outcomes and 5) Study quality (using the
Drummond Checklist- see section below for more detail). More
detail on the types of data abstracted by study can be found in
Table S2. Data from both reviewers was compared to ensure
accuracy of data abstraction. Any differences between reviewers
Table 2. Key cost components extracted from studies included in review (Adjusted to 2011 USD).*
Author,Year Full LTBI tx cost Adverse event costActive TB cost TST test cost IGRA test cost
Burgos, 2009 $264** $272 $11,271 N/A $21
de Perio, 2009 $540 $338
{ $63,120 $60 $49
Deuffic-Burban, 2010 $498 $6,814 $8,308 $17 $71
Diel, 2007 $299 N/A $28,007 $32 $79
Diel, 2007 $1,577 N/A $24,679 $39 $219
Kowada, 2010 $910 $14,006 $17,508 $109 $117
Kowada, 2010 $574 $13,245 $16,556 N/A $92
Kowada, 2008 $472 $10,898 $13,623 $121 $118
Linas, 2011 $462 $183 $13,378 $42 $52
Marra, 2008 $462 $698 $17,077 $28 $50
Oxlade, 2007 $512 $6,293 $25,553 $15 $47
Pareek, 2011 $224 $2,344 $5318 N/A $77
Pooran, 2010 $953 $1143 $13,849 $29 1) T-Spot: $100 2) QFT: $82
*List is not a comprehensive list of all costs included in studies, but is restricted to those costs included in common decision model described in main text.
N/A=Cost not included in study.
Full LTBI tx cost=includes cost for complete regimen cited in publication.
Active TB Cost=cost for a passively diagnosed Active case.
IGRA test cost=All studies considered Quantiferon, except Reference (12) (T-Spot only), Reference (16) (generic IGRA) and Reference (20) (included both QFN and T-
spot).
**Cost is for drugs and incentives only. Administrative and delivery expenses associated with LTBI treatment are included in the fixed program costs of 150 US$ (2007)
per year per study participant. These additional costs are not accounted for in any of the costs categories listed above.
{Cost shown for mild hepatitis.
doi:10.1371/journal.pone.0056044.t002
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PLOS ONE | www.plosone.org 3 March 2013 | Volume 8 | Issue 3 | e56044were resolved by discussion with a third reviewer. Authors were
contacted for clarification or if key information was missing.
Assessment of study quality. For each study, the overall
methodological quality of each study was evaluated using the
Drummond et al. 35 item checklist [7]. Each individual item was
scored using the mutually exclusive categories ‘‘Yes’’, ‘‘No’’, ‘‘Not
clear’’ or ‘‘Not applicable’’. A detailed qualitative comparison of
the results provided in the text and abstract conclusion was also
conducted.
Summarizing Variability in Study Inputs and Predicted
Results
For each study the following model inputs were abstracted: test
characteristics, transitional probabilities (eg risk of disease if
infected), and costs - particularly the specific components of the
cost for IGRA and TST. Predicted outcomes abstracted included:
cost per person screened and effectiveness measures (QALYs or
active cases) by test scenario. All costs were converted to US
dollars [8–11] and adjusted for inflation to 2011 US dollars [12].
Figure 1. Flow Chart of Study Selection.
doi:10.1371/journal.pone.0056044.g001
Table 3. Summary of Studies included in Review.
Authors
Year
Published Population
Mean age at start of
analysis (Basecase)(yrs) Reference
Burgos et al. 2009 Mexico- high TB/HIV risk sub population Adult (13)
de Perio et al. 2009 US Health Care workers 35 (14)
Deuffic-Burban et al. 2010 France, Contacts 35 (15)
Diel et al. 2007 Germany, Close contacts 20 (16)
Diel et al. 2007 Swiss, Contacts 20 (or 40) (17)
Kowada et al. 2010 Japan, Rheumatoid Arthritis patients 40 (18)
Kowada et al. 2010 Japan, elderly 65 (19)
Kowada et al. 2008 Japan, contacts 20 (20)
Linas et al. 2011 US, 19 different high risk groups Risk groups varied by age (21)
Marra et al. 2008 Canada, Contacts (mix of foreign born/
Canadian born/Aboriginal)
Age Weighted (16–35, 36–55, .56) (22)
Oxlade et al. 2007 Canada, Migrants or contacts 35 (23)
Pareek et al. 2011 UK, Migrants 35 yrs and younger (24)
Pooran et al. 2010 UK, Contacts Not specified (25)
doi:10.1371/journal.pone.0056044.t003
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PLOS ONE | www.plosone.org 4 March 2013 | Volume 8 | Issue 3 | e56044Assessment of Impact of Variability in Study Inputs using
a Common Model
Decision analysis model. We developed a common deci-
sion analysis Markov model using TreeAge software (TreeAge,
Version 2011) that incorporated the basic structure and conse-
quences of all of the models used in the studies included in the
review. As shown in Figure S1, the model simulates two identical
population cohorts, some of whom are infected with TB. In the
first year of the simulation, the first cohort is tested with an IGRA
test, while the second is tested with a TST. Depending on the
underlying TB health state of the population, and the character-
istics of the test being used, the population falls into one of four
mutually exclusive states (true positive, false positive, true negative
or false negative). Depending on the state, various consequences
ensue. For example, for those who are test positive, some of the
population may adhere to treatment and complete an effective
course of treatment, resulting in no negative outcome. Non-
completion and/or ineffective therapy can also occur however,
which results in the development of active TB- a negative
predicted outcome. Adverse events can also occur to anyone who
is treated, regardless of underlying TB health state. Once the
cohort completes the screening and treatment process in the first
year of the model, those that are infected and remain with LTBI
will cycle into an ‘‘infected state’’ in the next year of the model and
may later reactivate and develop active disease. Those who cure
after prophylactic therapy, or reactivate to active disease do not
continue to cycle in subsequent years.
Assessing impact of input variability on predicted
results. In this common model all pathogenetic and cost inputs
were defined using the distribution of input values used in the
different studies included in the review. These cost and input
values that affect effectiveness are summarized in Tables 1 and 2.
Monte Carlo probabilistic sensitivity analysis was used over 10,000
iterations to define the distribution of outcomes (costs and
effectiveness) for each test scenario. Effectiveness was defined as
the probability of being an active case. Percentiles (2.5
th and
97.5
th) were calculated for each distribution and predicted results
were plotted in order to visually compare results.
One way sensitivity analysis was then conducted on each
variable included in this common decision analysis model to
quantify the relative impact on predicted total costs over a 20 year
analytic horizon of differences in the study inputs. For this analysis,
the input range for each variable was taken from the maximum
and minimum of values used in the different studies included in
the review. The spread (calculated as the difference between the
lowest predicted outcome value, and the highest expected value)
and potential influence (calculated as the Spread divided by the
mean expected value for each test scenario) of each variable was
calculated.
Table 4. Predicted Effectiveness by Screening Strategy.
Study Author, Year
Effectiveness
Measure
Population/BCG
vaccination status
Effectiveness
with TST
Effectiveness
with IGRA
Gain in effectiveness using IGRA
(vs TST)
life time analytic horizon
De Perio, 2009 QALYs BCG –ve 23.55657 23.55671 0.00014 QALYs (0.05 days)
QALYs BCG +ve 23.55751 23.55826 0.00075 QALYs (0.27 days)
Deuffic-Brown, 2010 Life expectancy BCG +ve 25.072 25.073 0.001 Yrs (0.37 days)
Kowada, 2010 QALYs BCG –ve 22.98153 23.03499 0.053 QALYs (19.51 days)
QALYs BCG +ve 22.98153 23.03499 0.053 QALYs (19.51 days)
Kowada, 2010 QALYs BCG +ve NA 14.6516 NA
Kowada, 2008 QALYs BCG +ve 28.1079 28.1099 0.002 QALYs (0.73 days)
Linas, 2011 Life expectancy Close contacts 23.43917 23.44 0.00083 Yrs (0.30 days)
Life expectancy Recent immigrant 25.6925 25.6925 0 Yrs (0 days)
20 year analytic horizon
Burgos, 2009 QALYs BCG +ve NA 11.99 NA
Active cases BCG +ve NA 0.177 NA
Diel, 2007 Active cases* Mostly BCG+ve 0.0058 0.0058 0 Cases prevented
Diel, 2007 Active cases Mostly BCG+ve 0.0158 0.0196 20.018 Cases prevented**
Marra, 2008 QALYs Foreign born BCG –ve 15.1141 15.1145 0.0004 QALYs (0.15 days)
QALYs Foreign born BCG +ve 15.1203 15.1206 0.0003 QALYs (0.11 days)
Active cases Foreign born BCG –ve 0.0127 0.0126 0.0001 Cases prevented
Active cases Foreign born BCG +ve 0.0064 0.0063 0.0001 Cases prevented
Oxlade, 2007 Active cases BCG +ve or BCG 2ve 0.085 0.085 0 Cases prevented
Pareek, 2011 Active cases BCG not specified NA 0.00834 NA
2 year analytic horizon
Pooran, 2010 Active cases BCG not specified 0.00452 0.0038 (TSPOT)/
0.00403 (QFN)
0.00072 Cases prevented (TSPOT)/
0.00049 Cases prevented QFN)
*TB cases predicted in test positive in absence of intervention (treatment).
**Negative sign indicates more cases predicted with IGRA strategy relative to TST.
doi:10.1371/journal.pone.0056044.t004
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Studies Included in Review
As shown in Figure 1, the initial search found 714 unique
references. After review of titles, abstracts and full text, 11 studies
met the inclusion criteria and were included in the review. Two
additional studies published after the initial review was conducted
were added when a search update was performed. A summary of
the 13 studies included in the review is provided in Table 3 [13–
25]. Studies mostly considered populations in high income
countries. A variety of study sub-populations were considered
including contacts, immigrants, health care workers.
Study Quality
For all studies included in the review, the average proportion of
‘‘Yes’’ values given on the quality checklist was 72%. The
breakdown of Yes or No/Not clear for each of the 35 checklist
items is summarized in Figure S2. The following items from the
checklist had the lowest scores across studies; 1) Item 7: The choice
of form of economic evaluation is justified in relation to the
questions addressed (8% Yes), 2) Item 10: Details of the methods of
synthesis or meta-analysis of input values are given (if based on a
synthesis of a number of studies) (27% Yes), 3) Item 13: Details of
the subjects from whom valuations were obtained were given (33%
Yes), 4) Item 14: Productivity changes (if included) are reported
separately (25% Yes), 5) Item 27: The choice of variables for
sensitivity analysis is justified (38% Yes). A comparison of the text
result and abstract conclusion showed discordance in many studies
(Summarized in Table S3). The result provided in the text and
abstract conclusions on cost effectiveness were totally consistent in
only 5 studies.
Variability of Inputs
Key epidemiologic model inputs reported in studies varied
extensively, as shown in Table 1. More detail on these inputs is
provided in Table S4. Even after adjustment for inflation and
currency, cost inputs included in studies also varied widely
(Table 2). For example, the test cost for TST varied from $17 to
$121 (2011 USD) and for IGRA, from $21 to $219 (2011 USD).
An in depth examination of costing components of these
parameters (Table S5) showed that the approaches to costing
were different in all studies. For example, 6 studies included costs
from the patient perspective, 9 explicitly stated that they included
‘‘indirect’’ or costs for medical staff time to conduct the tests, and 7
explicitly stated that blood draw/phlebotomy costs associated with
the IGRA were included.
Variability of Predicted Results
In all studies, predicted effectiveness measures (QALYs gained
or active cases prevented) were almost identical with all test
scenarios (Table 4). QALYs gained from use of IGRA relative to
Table 5. Predicted Total Cost per person in 2011 USD by Screening Strategy.
Study Author, Year Population TST IGRA
Cost difference
(IGRA vs TST)*
life time analytic horizon
de Perio, 2009 BCG –ve $280 $262 -$18
BCG +ve $287 $177 -$110
Deuffic-Brown, 2010 BCG +ve $805 $703 -$102
Kowada, 2010 BCG –ve $1,920 $1,099 -$821
BCG +ve $2,206 $1,099 -$1,107
Kowada, 2010 BCG +ve NA $551 NA
Kowada, 2008 BCG +ve $625 $513 -$112
Linas, 2011 Close contacts $125, 610 $125, 620 $10
Recent immigrant $122,700 $122,700 $0
20 year analytic horizon
Burgos, 2009 BCG +ve No data on total cost No data on total costNA
Diel, 2007 BCG +ve $342 $271 -$71
Diel, 2007 Mostly BCG+ve $1,376 $748 -$628
Marra, 2008 Mostly BCG+ve $495 $525 $30
Foreign born BCG 2ve $460 $452 -$8
Oxlade, 2007 Foreign born BCG – ve $307 $348 $41
Foreign born BCG +ve (infancy) $321 $348 $27
Foreign born BCG +ve (older) $382 $348 -$34
Pareek, 2011 BCG not specified NA $142 NA
2 year analytic horizon
Pooran, 2010 BCG not specified $327 $371 (Tspot)/$369
(QFN)
$295 (TST/TSpot) $285
(TST/QFN)
*A negative number represents a savings with IGRA relative to TST.
doi:10.1371/journal.pone.0056044.t005
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PLOS ONE | www.plosone.org 6 March 2013 | Volume 8 | Issue 3 | e56044use of TST are also shown as days of life gained, to emphasize the
very small differences in effectiveness. Of all studies that compared
effectiveness with use of IGRA versus TST, only one study
predicted a gain of more than 1 day with use of the IGRA over an
analytic horizon of 20 years of more. On the other hand, predicted
cost differences between use of IGRA and TST varied widely
between studies, and between sub-populations considered within
the same study (Table 5).
Assessment of Impact of Variability of Study Inputs using
a Common Model
The distribution of predicted effectiveness (Figure 2a) and costs
(Figure 2b) largely overlapped when these outcomes were
predicted from Monte Carlo simulations using our common
decision analysis model. The 2.5
th and 97.5
th percentiles for
predicted effectiveness (probability of being an active case) were
very similar at 0.246% and 4.07% for the TST strategy and
0.244% and 3.98% for the IGRA strategy. Predicted costs showed
more of a difference between strategies with the 2.5
th and 97.5
th
percentiles for the TST strategy at $398 and $2251 and for the
IGRA strategy at $279 and $1953.
Using the same model, when the model inputs were varied in
one way sensitivity analyses, the predicted spread of costs was large
(Table 6). For both strategies the parameter with the greatest
spread, and thus the greatest potential influence in the model, was
the ‘‘prevalence of LTBI’’ (Potential influence: 147% and 97% for
Figure 2. Probability of predicting different expected values using common decision analysis model (10,000 iterations) with IGRA
or TST test strategy over 20 years. A. Predicted Effectiveness. B. Predicted Costs.
doi:10.1371/journal.pone.0056044.g002
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Input
Range of input
values for each
variable (defined
using base case
value reported in
studies in review)
IGRA strategy (Mean
expected value: total
cost=$855)
TST strategy (Mean expected
value: total cost=$1081)
Comment on justification for the variability
of inputs used by the different studies
SPREAD of
expected
values
(|lowest
value-
highest
value|)
POTENTIAL
INFLUENCE
(Spread/
mean
expected
value)
SPREAD of
expected
values (|lowest
value- highest
value|)
POTENTIAL
INFLUENCE
(Spread/mean
expected value)
Prevalence of LTBI 5% to 58% $1,258 147% $1,053 97% Variability in probabilities justified: Differences can
be justified by the consideration of different
populations and sub-groups.
Reactivation rate
(annual) in the absence
of effective LTBI
therapy
0.02% to 1.25% $982 115% $997 92% Variability in probabilities predominantly unjustified:
Differences could be justified based on study
population (ie. immunosuppressed, close contacts
etc.), however inputs used in 11/13 studies were for
the general population. In only 2 studies of close
contacts were higher reactivation rates used.
Cost of treating
active TB
$5318 to $63120 $903 106% $916 85% Variability in costs predominantly unjustified:A l l
studies should include similar costing components.
Costs should be similar for high income settings.
Some variability could be due to economic
perspective (eg. Study 2 included indirect costs).
Cost of treating LTBI $224 to $1577 $375 44% $704 65% Variability in costs partially justified: All studies
should include similar costing components. Costs
should be similar as most are high income settings.
Duration of prophylactic regimen will result in some
justified variability in costing (6 studies assumed
9INH, 5 assumed 6INH and 1 assumed 3HR).
Specificity of TST 15% to 99% 22 $635 59% Variability in probabilities partially justified:
Differences could be justified based on BCG status
of study population. However, within each sub
population we should see similar estimates that
have been derived from meta analyses.
Probability of an
adverse event from
LTBI therapy
0 to 18% $318 37% $558 52% Variability in probabilities predominantly unjustified:
Most studies consider young populations that
should experience similar types and rates of
adverse events. One study considered an elderly
population with justified use of higher rates of
adverse events.
Completion rate for
LTBI therapy
21% to 100% $271 32% $267 25% Variability in probabilities partially justified: Estimates
should be similar for studies set in general
population. Differences based on duration of
regimen justified, yet estimates with same duration
should be similar.
Cost of an adverse
event
$183 to $14006 $236 28% $442 41% Variability in costs predominantly unjustified: All
studies should include similar events with similar
costing components.
Cost of IGRA/TST $21 to $219/$15 to
$121
$198 23% $106 10% Variability in costs predominantly unjustified: All
studies should include similar costing components
for basic screening. Costs should be similar for high
income settings.
Efficacy of LTBI
therapy
65% to 90% $114 13% $112 10% Variability in probabilities partially justified:
Differences justified for different regimens.
However, for each regimen, estimate should be
similar and derived from previously published meta
analyses.
Sensitivity of IGRA 76% to 99% $32 4% 22 Variability in probabilities predominantly unjustified:
All studies should use similar estimates derived
from previously published meta analyses.
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of effective LTBI therapy was also important (Potential Influence:
115% and 92% for IGRA and TST respectively). The cost of
treating active TB and LTBI followed in the ranking of influential
parameters. The full ranking of all parameters is reported in
Table 6.
Discussion
Thirteen cost effectiveness papers were reviewed in our study.
Differences in estimated effectiveness were consistently very small
in all studies. Although in general quality was deemed to be
satisfactory, assumed input costs and transitional probabilities were
very inconsistent. As a result, predicted costs and cost-effectiveness
varied widely. Although CEAs are supposed to provide objective
evidence for decision making, when studies present widely
discrepant results they are less useful. A lack of standardization
and divergence in CEA methods led to the development of the
recommendations set out by the Panel on Cost Effectiveness in
Health and Medicine in 1996 [26]. Despite the existence of
recommendations such as these, many issues still remain in how
CEAs are conducted. Some problems appear to stem from how
well authors can implement guidelines in practical terms.
However, the appropriateness of guidelines for specific areas of
evaluative research is also of some concern.
The detailed review of methods performed in this systematic
review identified several specific methodologic issues relating to
data analysis, presentation and interpretation of CEA findings.
The implications of some of these issues are discussed in more
detail below:
Selection of Study Inputs
The estimates of pathogenetic, cost inputs and test character-
istics used in different studies varied widely. Even though these
inputs played an important role in determining results, much of
the variability in input values was not well justified. As highlighted
in the Drummond et al [7] evaluative criteria of economic studies,
whenever possible, inputs should be derived from systematic
reviews and meta analyses.
Approach to Costing
The approach to costing, including which specific cost
components were included, varied by study; this had an important
impact on determining cost effectiveness. The Recommendations
of the Panel on Cost effectiveness in Health and Medicine [26] for
the ideal approach for costing should be followed whenever
possible. However, authors are often faced with practical
limitations, and in certain cases may have to prioritize using cost
data that are easily obtainable.
Use of the Effectiveness Measure in Diagnostic Studies
The difference in effectiveness measure between test strategies
was so small as to be clinically meaningless. Although cost
effectiveness is determined by differences in effectiveness and
differences in cost, the latter was identified as the main
determinant of study results in this particular area. The QALY
is recommended by The Panel on Cost effectiveness in Health and
Medicine as the ideal measure of health effectiveness [26].
However this study demonstrates a weakness of using this measure
for diagnostic studies. Given that none of the conventional
measures of effectiveness were able to capture meaningful
differences between the two testing strategies for the detection of
latent TB infection, the focus of economic studies in this area
should be placed on cost alone.
Presentation and Interpretation of Cost Effective Data
Issues were identified in the presentation and interpretation of
data, with many studies not clearly presenting data on which test
was ‘‘the most cost effective’’. Conclusions that a certain strategy
was ‘‘cost effective’’ or ‘‘highly cost effective’’ were frequently not
defined, or based on a willingness to pay threshold of $50,000 per
QALY gained. This benchmark was developed for evaluation of
cost-effectiveness of interventions for end stage renal disease in the
US in the 1980s [27], so may not be appropriate for the testing
scenarios, countries, or populations being considered.
Some of these findings are consistent with the assessment of
conceptual issues related to modeling and economic analyses of
TB diagnostics by Dowdy et al. [28]. Although they did not focus
on IGRAs for diagnosing LTBI, they suggested that current
approaches to economic analyses in diagnostic research need to be
Table 6. Cont.
Input
Range of input
values for each
variable (defined
using base case
value reported in
studies in review)
IGRA strategy (Mean
expected value: total
cost=$855)
TST strategy (Mean expected
value: total cost=$1081)
Comment on justification for the variability
of inputs used by the different studies
SPREAD of
expected
values
(|lowest
value-
highest
value|)
POTENTIAL
INFLUENCE
(Spread/
mean
expected
value)
SPREAD of
expected
values (|lowest
value- highest
value|)
POTENTIAL
INFLUENCE
(Spread/mean
expected value)
Specificity of IGRA 96% to 100% $31 4% 22 Variability in probabilities predominantly unjustified:
All studies should use similar estimates derived
from previously published meta analyses.
Sensitivity of TST 67% to 99% 22 $45 4% Variability in probabilities predominantly unjustified:
All studies should include similar estimates that
have been derived from meta analyses.
doi:10.1371/journal.pone.0056044.t006
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cost effectiveness.
Nienhaus et al. also recently performed a systematic review of
TB screening strategies [29]. Unlike our study, their objective was
to summarize the evidence in order to make a recommendation
regarding a preferred strategy for LTBI screening. Although the
authors acknowledged differences in input costs, model assump-
tions, strategies evaluated and outcomes, they still recommended a
preferred test strategy, but cautioned that more evidence is needed
for ‘‘generally accepted inputs for economic analysis’’.
Cost effectiveness analyses are an essential tool for the
evaluation of health care practises, and are being used more and
more widely to prioritize interventions. Our analysis highlights
some of the specific methodological issues observed in published
CEA of IGRA screening. Although guidelines exist to standardize
such analyses, in many cases these guidelines were not followed,
although some aspects may not be relevant for diagnostic CEA.
More specific and relevant guidelines are needed, and we suggest
the following: 1. The development of standard inputs and
assumptions for use in modeling studies like those included in
our review would be useful. Standard sources could then be
routinely used as input data for modelling studies. 2. The
standardization of approaches to costing should also be encour-
aged so that all studies include similar cost components- ideally
from a societal perspective which includes the economic impact on
patients in addition to the impact on the health system. 3. The
choice of primary economic measure also needs to be considered
carefully in these types of studies. Based on our finding of no
substantial difference in effectiveness between testing strategies, for
this question – of comparing diagnostic strategies in LTBI -
economic analyses should focus exclusively on cost and resource
implications in the setting in question. 4. Finally, authors should
make much greater effort to present and interpret cost effective-
ness results in a more transparent manner. For example, standard
criteria of willingness to pay must be used and the setting clearly
stated when concluding if a study is ‘‘cost-effective’’. And, if the
difference in effectiveness is very small this should be explicitly
stated, and any conclusions about cost-effectiveness should be
avoided. Ultimately, these recommendations should improve
economic studies that evaluate diagnostic strategies for LTBI,
and increase their value for informing individual and public health
decisions.
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